Thyroid fine needle aspiration (FNA)
What is a Thyroid Fine Needle Aspiration (FNA)? The thyroid is a soft gland in the front of the neck,…Read more
As the scan involves an injection of radioactivity, it is not advisable in pregnant females.
This study may not be suitable for pregnant women. The benefit versus risk should be discussed with the nuclear medicine specialist.
Women who are breastfeeding and people who are the primary or sole carer for small children may need to make special preparations after the test to stop breastfeeding for a short time and to avoid close contact with young children due to the small amount of radioactivity released for a while after the test. Patients should discuss this with their referring doctor or the nuclear medicine practice where they will have the test for details. See nuclear medicine for further information about the precautions to take with nuclear medicine studies for breastfeeding patients and those in close contact with children.
Most scanners will have a weight limit ranging from 160-200 kilograms.
Generally there are no adverse reactions, but on rare occasion the patient may experience a metallic taste, tingling, flushing, nausea, erythema, diffuse rash, or headache. These effects are short-lived.
Conventional X-rays will detect disease involvement in 75-95% of cases with 80% sensitivity. However, radiography is unable to discriminate between active osteolytic areas and healed lesions.
Skeletal lesions in myeloma are rarely osteoblastic (bone forming or dense on plain X-rays or CT scanning) and hence radiopharmaceuticals such as technetium-99m-disphosphonate (bone scans) do not demonstrate an avid uptake. Reported sensitivity for multiple myeloma of routine bone scanning ranges from 40% to 60%.
MRI is superior to plain X-rays, but it is impractical for routine whole body survey, due to long imaging time and costs. Substitution of X-rays by MRI limited to the spine and pelvis would cause under-staging by 10%.
PET imaging is often complementary, but is not a substitute for a MIBI scan for detection of myeloma.
Page last modified on 26/7/2017.
RANZCR® is not aware that any person intends to act or rely upon the opinions, advices or information contained in this publication or of the manner in which it might be possible to do so. It issues no invitation to any person to act or rely upon such opinions, advices or information or any of them and it accepts no responsibility for any of them.
RANZCR® intends by this statement to exclude liability for any such opinions, advices or information. The content of this publication is not intended as a substitute for medical advice. It is designed to support, not replace, the relationship that exists between a patient and his/her doctor. Some of the tests and procedures included in this publication may not be available at all radiology providers.
RANZCR® recommends that any specific questions regarding any procedure be discussed with a person's family doctor or medical specialist. Whilst every effort is made to ensure the accuracy of the information contained in this publication, RANZCR®, its Board, officers and employees assume no responsibility for its content, use, or interpretation. Each person should rely on their own inquires before making decisions that touch their own interests.